We are an Israeli company founded in 2010
EMAS MED offers a ground-breaking service for the implementation of advanced genetic tests for cancer patients, having the largest possible range of tests. We collaborate with leading laboratories worldwide, with all hospitals in Israel and with the oncology community.
We offer the following genetic tests:
Patient-specific medicine is an approach that has been evolving in recent years. In order to treat cancer effectively, therapy must be tailored to the specific characteristics of each patient. This approach is called “Personalised Medicine”.
Cancer is, among other things, the result of changes in the genome (alterations in DNA), which are responsible for the formation and development of the disease. By determining a unique molecular profile for each patient, abnormalities in the function of genes and proteins that are responsible for the cancer process can be identified. The information obtained from the tests can help the doctor tailor treatment individually for the patient, taking into account the unique genetic characteristics of the tumour. In addition, these tests make it possible to rule out therapies that the tumour might be expected to respond to.
In simple terms, imagine two patients diagnosed with the same type of cancer, in the same location and of the same size. Although they will receive the same treatment, in many cases one will respond positively to treatment, while the other will not respond at all and the disease will progress. Why? Because every patient is different, and every tumour is different!
Molecular profile diagnosis is the most groundbreaking development of the last decade in the field of cancer diagnosis. Unlike imaging technologies such as X-ray, MRI, PET-CT, which examine the tumour as a collection of cells, a kind of ‘black box’, patient-specific medicine goes one step further, inside the cells, looking for the small molecules that are responsible for the tumour process, or, as they have been called, genes and proteins.
This diagnosis makes it possible to differentiate between two patients whose disease appears to be identical, since the differences, as mentioned earlier, are found in the same genetic mutations and protein expression.
Therefore, the determination of the molecular profile makes it possible to predict, for each patient individually, which therapies will be suitable for him or her, and to avoid unnecessary therapies that will have no benefit.
For further information and consultation, we are happy to help by telephone or via the contact form.
This test enables you to end long-term hormone treatment and avoid side effects!
Thanks to an innovative test, we will be able to individually and accurately determine whether you respond to long-term hormone treatment after 5 years.
The test saves more than 60% of women treated for breast cancer from long-term hormone treatment and its accompanying side effects.
The test increases the subjects’ confidence in deciding whether or not to continue hormone treatment.
The US-based Caris Life Sciences assay is the most comprehensive genomic assay for personalised cancer treatment matching, including full genome sequencing of the entire genome – approximately 23,000 genes (whole exome sequencing), at both the DNA and RNA levels.
Caris is the only company sequencing both DNA and RNA, and additionally performing immunohistochemical staining to detect the presence of the FOLR1 receptor – this staining is essential for matching a breakthrough drug that was recently approved for ovarian cancer patients and was even submitted to the health benefit basket this year.
The staining is carried out according to the Companion Diagnostics protocol – that is, according to the protocol approved to obtain the drug, so positive staining of the FOLR1 receptor in the Caris trial offers the chance of receiving a breakthrough therapy for the disease. Approximately 30 per cent of ovarian cancer patients will be positive for FOLR1 staining, which adds a unique dimension to the trial and significantly increases the chances of finding a personalised therapy in the Caris trial.
This is a precise blood test used to rule out aggressive prostate cancer. The 4Kscore test is much more accurate than the PSA test.
The Decipher genetic test actually answers one basic question – whether the tumour is ‘quiescent’ and has a low level of malignancy, requiring minimal treatment or observation, or whether it is a ‘wolf in sheep’s clothing’, with the potential to develop into an aggressive and life-threatening tumour. By focusing on the genes that regulate tumour growth, the malignancy of the tumour can be accurately tracked and the development of the disease can be predicted, for up to 10 years.
The test is performed on a biopsy or, in the case of a prostatectomy, on material from the prostatectomy itself. The genetic material from the sample, the RNA, is analysed by full sequencing using the Whole Transcriptome RNA method, and the activity levels of various genes are summarised by a unique algorithm that accurately assesses the degree of malignancy of the sample. Once the process is complete, a report is sent to the treating physician, describing the degree of malignancy of the tumour over a 10-year period and the recommended therapy.
It is worth remembering that without a genetic test – a test that verifies which genes have been attached to the growth of the tumour – the doctor is mainly left with a pathological examination, which is known for its low and subjective accuracy, depending mainly on the eyes of the pathologist who assesses the sample. The Gleason index, which pathologists use to assess the malignancy of a specimen, can vary between two pathology tests, and often the test gives an assessment that distorts the malignancy of the tumour.
Is the test covered by health insurers and insurance companies?
Significant reimbursements for the test can be obtained from health insurers and private insurance companies, depending on each test subject’s insurance type. Progenetics offers insurance consultations and will be happy to help and advise on this issue.
For additional information and consultations, we are happy to help by phone or via the contact form.
CARIS is the most comprehensive and precise tool for customising advanced cancer therapies.
Caris Life Sciences is a leading innovator in molecular science, focused on fulfilling the promise of precision medicine through quality and innovation. As the first to offer comprehensive molecular profiling in oncology, Caris is an industry leader with more than 150,000 tumours profiled.
Caris Molecular Intelligence is the first and most experienced comprehensive cancer profiling service designed to enable the delivery of precision medicine. Our comprehensive approach to cancer profiling assesses DNA, RNA and proteins to reveal the molecular blueprint to guide more precise and personalised treatment decisions. The Caris Molecular Intelligence report is generated for each patient and can help the clinician personalise cancer-specific therapies.
Biomarker analysis can help you and your doctor identify potential treatment options for your disease. Your doctor may consider molecular profiling if:
Tumour profiling from Caris Life Science® is only available for patients with solid tumours and must be ordered by a doctor.
Caris Molecular Intelligence uses multiple tumour profiling technologies to decode cancer and better understand the biology driving tumour growth. Biomarker results or a molecular blueprint from a tissue sample are then matched to anti-cancer therapies associated with benefit or non-benefit, as well as clinical trials for a given cancer. Caris Molecular Intelligence matches biomarkers to therapies using a comprehensive review of the strongest and most relevant clinical and scientific studies related to cancer. This information, or Molecular Intelligence, can be used by the clinician to personalise treatment, which can lead to a better response to treatment.
The report is a tool that provides a molecular blueprint to help the doctor assess and make more precise and individualised treatment decisions. The patient and doctor will establish a treatment plan that is based on a number of factors, including the report, availability of cancer drugs, medical history and other clinical factors.
Yes, through the Clinical Trials ConnectorTM, the report identifies clinical trial opportunities that are currently recruiting patients based on unique biomarkers in the tumour. Your doctor will determine if any of these trials may be suitable for you.
The Caris Molecular Intelligence® test is performed on solid tumour tissue that is routinely obtained during surgical removal of the tumour or from a biopsy sample. As tumour biomarkers can change over time and during treatment, the clinician may wish to obtain a more up-to-date tumour sample.
Once our laboratory receives the sample and the required documentation, the process usually takes 14-21 days. The report will be delivered directly to your doctor for review.
The MI Profile report containing the results is sent to your doctor via a secure email.
Caris Molecular Intelligence® uses multiple tumour profiling technologies to decode cancer and better understand the biology driving tumour growth. Biomarker results or a molecular blueprint from a tissue sample are then matched to anti-cancer drugs associated with benefit or non-benefit, as well as clinical trials for a particular cancer.
The Caris Molecular Intelligence® test can only be ordered by physicians. If you would like to explore the possibility of ordering tumor profiling from Caris Life Sciences®, please consult your oncologist or us.
***"We do not send spam
